Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug

Drug companies Jazz (JAZZ.O) and Hikma (HIK.L) must face claims that they schemed to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing health plans to pay higher prices, a U.S. judge in California has ruled.